Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Immediate release Paliperidone · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Immediate release (IR) Paliperidone | DRUG | - |
Inclusion Criteria: * Patients must have a diagnosis of schizophrenia or schizoaffective disorder as defined by DSM-IV criteria, with no exacerbation of psychosis for at least 3 months prior to screening * Patients must have a normal 12-lead ECG at screening and on Day -1, including: Normal sinus r...
Immediate Release Paliperidone is an investigational small molecule being studied for the treatment of schizophrenia. It is currently in Phase 1 clinical development. The drug is being developed by Johnson & Johnson (JNJ) for use in psychiatry.
Immediate Release Paliperidone is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 1 clinical development for schizophrenia.
Immediate Release Paliperidone is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed for this candidate.
Immediate Release Paliperidone has been studied in one completed Phase 1 clinical trial, NCT00791349, titled 'A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone'. The trial enrolled 141 participants with schizophrenia or schizoaffective disorder.
Immediate Release Paliperidone is a specific formulation of the drug paliperidone. The 'immediate release' designation refers to how the medication is released in the body, as opposed to extended-release versions. This formulation is being studied for schizophrenia.